vs
ExlService Holdings, Inc.（EXLS）与West Pharmaceutical Services（WST）财务数据对比。点击上方公司名可切换其他公司
West Pharmaceutical Services的季度营收约是ExlService Holdings, Inc.的1.5倍（$805.0M vs $542.6M），West Pharmaceutical Services净利率更高（16.4% vs 11.1%，领先5.3%），ExlService Holdings, Inc.同比增速更快（12.7% vs 7.5%），West Pharmaceutical Services自由现金流更多（$175.0M vs $106.5M），过去两年ExlService Holdings, Inc.的营收复合增速更高（11.5% vs 7.6%）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
美国West Pharmaceutical Services是注射用药品包装及给药系统的设计和制造商，1923年成立，总部位于宾夕法尼亚州埃克斯顿。成立初期主营注射类药物包装用橡胶组件，曾为青霉素和胰岛素生产商提供符合无菌要求的配套产品。
EXLS vs WST — 直观对比
营收规模更大
WST
是对方的1.5倍
$542.6M
营收增速更快
EXLS
高出5.2%
7.5%
净利率更高
WST
高出5.3%
11.1%
自由现金流更多
WST
多$68.5M
$106.5M
两年增速更快
EXLS
近两年复合增速
7.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $805.0M |
| 净利润 | $60.2M | $132.1M |
| 毛利率 | 38.6% | 37.8% |
| 营业利润率 | 14.4% | 19.5% |
| 净利率 | 11.1% | 16.4% |
| 营收同比 | 12.7% | 7.5% |
| 净利润同比 | 18.9% | 1.5% |
| 每股收益（稀释后） | $0.38 | $1.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXLSWST
| Q4 25 | $542.6M | $805.0M | ||
| Q3 25 | $529.6M | $804.6M | ||
| Q2 25 | $514.5M | $766.5M | ||
| Q1 25 | $501.0M | $698.0M | ||
| Q4 24 | $481.4M | $748.8M | ||
| Q3 24 | $472.1M | $746.9M | ||
| Q2 24 | $448.4M | $702.1M | ||
| Q1 24 | $436.5M | $695.4M |
净利润EXLSWST
| Q4 25 | $60.2M | $132.1M | ||
| Q3 25 | $58.2M | $140.0M | ||
| Q2 25 | $66.1M | $131.8M | ||
| Q1 25 | $66.6M | $89.8M | ||
| Q4 24 | $50.7M | $130.1M | ||
| Q3 24 | $53.0M | $136.0M | ||
| Q2 24 | $45.8M | $111.3M | ||
| Q1 24 | $48.8M | $115.3M |
毛利率EXLSWST
| Q4 25 | 38.6% | 37.8% | ||
| Q3 25 | 38.5% | 36.6% | ||
| Q2 25 | 37.7% | 35.7% | ||
| Q1 25 | 38.6% | 33.2% | ||
| Q4 24 | 38.1% | 36.5% | ||
| Q3 24 | 37.8% | 35.4% | ||
| Q2 24 | 37.1% | 32.8% | ||
| Q1 24 | 37.4% | 33.1% |
营业利润率EXLSWST
| Q4 25 | 14.4% | 19.5% | ||
| Q3 25 | 14.4% | 20.8% | ||
| Q2 25 | 15.8% | 20.1% | ||
| Q1 25 | 15.7% | 15.3% | ||
| Q4 24 | 14.8% | 21.3% | ||
| Q3 24 | 14.7% | 21.6% | ||
| Q2 24 | 13.7% | 18.0% | ||
| Q1 24 | 14.1% | 17.7% |
净利率EXLSWST
| Q4 25 | 11.1% | 16.4% | ||
| Q3 25 | 11.0% | 17.4% | ||
| Q2 25 | 12.8% | 17.2% | ||
| Q1 25 | 13.3% | 12.9% | ||
| Q4 24 | 10.5% | 17.4% | ||
| Q3 24 | 11.2% | 18.2% | ||
| Q2 24 | 10.2% | 15.9% | ||
| Q1 24 | 11.2% | 16.6% |
每股收益（稀释后）EXLSWST
| Q4 25 | $0.38 | $1.82 | ||
| Q3 25 | $0.36 | $1.92 | ||
| Q2 25 | $0.40 | $1.82 | ||
| Q1 25 | $0.40 | $1.23 | ||
| Q4 24 | $0.31 | $1.78 | ||
| Q3 24 | $0.33 | $1.85 | ||
| Q2 24 | $0.28 | $1.51 | ||
| Q1 24 | $0.29 | $1.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $791.3M |
| 总债务越低越好 | $298.6M | $202.8M |
| 股东权益账面价值 | $912.7M | $3.2B |
| 总资产 | $1.7B | $4.3B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资EXLSWST
| Q4 25 | $328.4M | $791.3M | ||
| Q3 25 | $390.1M | $628.5M | ||
| Q2 25 | $353.3M | $509.7M | ||
| Q1 25 | $331.4M | $404.2M | ||
| Q4 24 | $340.6M | $484.6M | ||
| Q3 24 | $325.8M | $490.9M | ||
| Q2 24 | $276.1M | $446.2M | ||
| Q1 24 | $246.2M | $601.8M |
总债务EXLSWST
| Q4 25 | $298.6M | $202.8M | ||
| Q3 25 | $354.8M | $202.7M | ||
| Q2 25 | $260.0M | $202.6M | ||
| Q1 25 | $307.3M | $202.6M | ||
| Q4 24 | $288.5M | $202.6M | ||
| Q3 24 | $344.7M | $202.6M | ||
| Q2 24 | — | $205.8M | ||
| Q1 24 | — | $206.2M |
股东权益EXLSWST
| Q4 25 | $912.7M | $3.2B | ||
| Q3 25 | $952.4M | $3.1B | ||
| Q2 25 | $1.1B | $2.9B | ||
| Q1 25 | $1.0B | $2.7B | ||
| Q4 24 | $929.9M | $2.7B | ||
| Q3 24 | $907.6M | $2.8B | ||
| Q2 24 | $852.6M | $2.6B | ||
| Q1 24 | $803.3M | $2.7B |
总资产EXLSWST
| Q4 25 | $1.7B | $4.3B | ||
| Q3 25 | $1.7B | $4.1B | ||
| Q2 25 | $1.7B | $4.0B | ||
| Q1 25 | $1.7B | $3.6B | ||
| Q4 24 | $1.6B | $3.6B | ||
| Q3 24 | $1.6B | $3.7B | ||
| Q2 24 | $1.5B | $3.5B | ||
| Q1 24 | $1.4B | $3.6B |
负债/权益比EXLSWST
| Q4 25 | 0.33× | 0.06× | ||
| Q3 25 | 0.37× | 0.07× | ||
| Q2 25 | 0.25× | 0.07× | ||
| Q1 25 | 0.30× | 0.08× | ||
| Q4 24 | 0.31× | 0.08× | ||
| Q3 24 | 0.38× | 0.07× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $251.1M |
| 自由现金流经营现金流 - 资本支出 | $106.5M | $175.0M |
| 自由现金流率自由现金流/营收 | 19.6% | 21.7% |
| 资本支出强度资本支出/营收 | 2.0% | 9.5% |
| 现金转化率经营现金流/净利润 | 1.95× | 1.90× |
| 过去12个月自由现金流最近4个季度 | $298.1M | $468.9M |
8季度趋势，按日历期对齐
经营现金流EXLSWST
| Q4 25 | $117.4M | $251.1M | ||
| Q3 25 | $120.7M | $197.2M | ||
| Q2 25 | $109.4M | $177.1M | ||
| Q1 25 | $3.2M | $129.4M | ||
| Q4 24 | $105.3M | $190.1M | ||
| Q3 24 | $110.1M | $180.1M | ||
| Q2 24 | $74.9M | $165.0M | ||
| Q1 24 | $-21.9M | $118.2M |
自由现金流EXLSWST
| Q4 25 | $106.5M | $175.0M | ||
| Q3 25 | $106.4M | $133.9M | ||
| Q2 25 | $95.0M | $101.9M | ||
| Q1 25 | $-9.7M | $58.1M | ||
| Q4 24 | $95.3M | $85.2M | ||
| Q3 24 | $97.3M | $98.8M | ||
| Q2 24 | $62.8M | $64.8M | ||
| Q1 24 | $-33.1M | $27.6M |
自由现金流率EXLSWST
| Q4 25 | 19.6% | 21.7% | ||
| Q3 25 | 20.1% | 16.6% | ||
| Q2 25 | 18.5% | 13.3% | ||
| Q1 25 | -1.9% | 8.3% | ||
| Q4 24 | 19.8% | 11.4% | ||
| Q3 24 | 20.6% | 13.2% | ||
| Q2 24 | 14.0% | 9.2% | ||
| Q1 24 | -7.6% | 4.0% |
资本支出强度EXLSWST
| Q4 25 | 2.0% | 9.5% | ||
| Q3 25 | 2.7% | 7.9% | ||
| Q2 25 | 2.8% | 9.8% | ||
| Q1 25 | 2.6% | 10.2% | ||
| Q4 24 | 2.1% | 14.0% | ||
| Q3 24 | 2.7% | 10.9% | ||
| Q2 24 | 2.7% | 14.3% | ||
| Q1 24 | 2.6% | 13.0% |
现金转化率EXLSWST
| Q4 25 | 1.95× | 1.90× | ||
| Q3 25 | 2.08× | 1.41× | ||
| Q2 25 | 1.66× | 1.34× | ||
| Q1 25 | 0.05× | 1.44× | ||
| Q4 24 | 2.08× | 1.46× | ||
| Q3 24 | 2.08× | 1.32× | ||
| Q2 24 | 1.63× | 1.48× | ||
| Q1 24 | -0.45× | 1.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
WST
| Proprietary Products | $661.8M | 82% |
| Contract Manufactured Products | $143.2M | 18% |
| Affiliated Entity | $3.3M | 0% |
